Evidence map›Paper›PMID 41345689›Full record

ArticleTrials2025

Persistent carry-over in a two-period randomised crossover design for behavioural interventions without the expectation of return to baseline after intervention cessation.

Stefan Tino Kulnik, Anna Eleonora Carrozzo, Rik Crutzen

Abstract read
In one paragraph

Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Stefan Tino KulnikSalzburg Research Forschungsgesellschaft m.b.H., Jakob Haringer Strasse 5/3, Salzburg, 5020, Austria. stefan.kulnik@salzburgresearch.at.ORCID http://orcid.org/0000-0001-5419-6713
Anna Eleonora CarrozzoSalzburg Research Forschungsgesellschaft m.b.H., Jakob Haringer Strasse 5/3, Salzburg, 5020, Austria.
Rik CrutzenLudwig Boltzmann Institute for Digital Health and Prevention, Lindhofstrasse 22, Salzburg, 5020, Austria.

Funding

Salzburger Landesregierung 20204-WISS/263/6-6022
6 · The paper itself

Abstract

backgroundThe two-period randomised crossover design can be advantageous over the parallel-group randomised controlled design with two study arms, yielding greater statistical power and requiring smaller sample sizes. However, a general assumption of the crossover design is that study participants return to their stable baseline state after the experimental treatment has been withdrawn, either immediately or following a wash-out period. MAIN BODY: In this article, we describe an alternative paradigm for the crossover design, which assumes that participants do not return to their baseline after the experimental treatment has discontinued-in other words, a paradigm under which a persistent carry-over effect is anticipated and even desired after intervention cessation. Such a paradigm is suitable, for example, when investigating behaviour change interventions that aim to establish long-lasting health behaviours through, for example, patient education or counselling. We present sample size calculations and statistical simulations to illustrate that under this alternative paradigm, the randomised crossover design can still maintain greater power than the parallel-group randomised controlled design. Statistical simulations show that, under realistic assumptions of partial or full carry-over, the crossover design can maintain equal or greater power than the parallel-group design, particularly when between-subject heterogeneity is non-negligible.

conclusionTrialists may consider this approach when the nature or intention of the experimental treatment is contrary to the assumption of return to baseline.

Indexed as

Behavior TherapyHealth BehaviorRandomized Controlled Trials as TopicResearch DesignComputer SimulationCross-Over StudiesHumansSample SizeTime FactorsTreatment OutcomeBehaviour changeCrossoverEffectivenessEfficacyExperimental designsPowerSample size

Identifiers

PMID41345689
PMCPMC12676868

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.